Inimmune to Present on Our Novel Cancer Immunotherapy INI-4001
Inimmune to present on their Novel Cancer Immunotherapy INI-4001 at the Medinvest Oncology Conference on December 6th, 2023
MISSOULA, MT, December 1, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel cancer immunotherapies and vaccine adjuvants and delivery systems, announced today that its Chief Operating Officer, Dr. David Burkhart, will give a presentation at the upcoming MedInvest Oncology Conference in Palo Alto California December 5-6th. The event brings […]
Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on our innovative vaccine and adjuvant programs on Wednesday, December 29, 2023 at the World Vaccine Congress (West Coast) in Santa Clara, CA
Missoula, MT, November 30, 2023 – Inimmune, a leading clinical stage biotech company focused on thedevelopment of novel vaccines and immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at World Vaccine Congress (West Coast). Innovative vaccine adjuvants and delivery technologies have demonstrated great progress for treatment and […]
Inimmune to Provide an Update on Our Vaccine and Adjuvant Programs
UM and Inimmune Receive $12.3 M NIH Contract to Advance New Adjuvant for Vaccines Targeting Bacterial and Fungal Infections
Contact: Jay Evans, research professor, UM Center for Translational Medicine director, 406-381-0573, jay.evans@umontana.edu. UM Leads $12.3M Contract to Advance TB VaccineUM News Service MISSOULA, Montana, October, 29, 2023 – The National Institutes of Health recently awarded a $12.3 million contract to the University of Montana to develop a novel vaccine adjuvant for use in a tuberculosis […]
Inimmune Collaborates with Boston Children’s Hospital to Develop Novel Adjuvants
MISSOULA, Montana, October, 24, 2023 – Inimmune Corporation, a clinical-stage biotechnology company focused on creating and developing innovative immunotherapeutics, announced that it has entered a research collaboration with Boston Children’s Hospital (BCH) to develop novel and innovative small molecule vaccine adjuvants. An adjuvant is added to some vaccines to enhance the immune response, thereby creating a […]
Inimmune to Participate and Update on Clinical Programs
Inimmune’s Chief Scientific and Strategy Officer, Dr. Jay Evans, will participate in BioJapan and provide a company update on clinical programs on Friday, October 13 in Yokohama, Japan
MISSOULA, MT, October 10, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at BioJapan (https://jcd-expo.jp/en/). New immunotherapy drugs and vaccine technologies have shown great promise in the treatment of allergy, cancer, […]
Inimmune to Present an Update on Clinical Stage Programs
Inimmune CSO Jay Evans to present an update on clinical stage programs at the International Precision Vaccine Conference in Rome, Italy on October 5-6
MISSOULA, Montana, September 26, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will be a speaker at the International Precision Vaccines Conference (https://precisionvaccines2023.com/) in Rome, Italy on October 5-6. The International Precision Vaccine Conference […]
